PharmAthene, Inc. : PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
January 12, 2012 at 12:55 am IST
By
Share
ANNAPOLIS, Md., Jan. 11,
2012/PRNewswire/ -- PharmAthene, Inc. (NYSE Amex:
PIP), a biodefense company developing medical
countermeasures against biological and chemical threats,
announced today that Eric I. Richman,
President and Chief Executive Officer will present at the
Noble Financial Capital Markets Eighth Annual Equity
Conference on Tuesday, January 17, 2012at
3:30 pm ESTin the Volga Room/Room 2 at the
Hard Rock Hotel, Hollywood Florida.
Mr. Richman will also be available to participate in
one-on-one meetings at the conference.
Event: Noble Financial Capital Markets 8th Annual
Equity Conference
Date: Tuesday, January 17, 2012
Place: Hollywood, Florida; Hard Rock
Hotel; Volga Room / Room 2
Time: 3:30 pm EST
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of
the United Statesand its allies by developing
and commercializing medical countermeasures against
biological and chemical weapons. PharmAthene's lead
product development programs include:
SparVax™ - a second generation recombinant protective
antigen (rPA) anthrax vaccine
Valortim® - a fully human monoclonal antibody for the
prevention and treatment of anthrax infection
Recombinant BChE - a novel bioscavenger for the
prevention and treatment of morbidity and mortality
associated with exposure to chemical nerve agents
In addition, pursuant to an opinion issued September
22, 2011from the DelawareCourt of
Chancery, PharmAthene is entitled to 50% of the profits
over 10 years from all sales of SIGA Technologies'
ST-246, and related products, a novel smallpox antiviral
agent being developed by SIGA for the treatment and
prevention of morbidity and mortality associated with
exposure to the causative agent of smallpox (once SIGA
receives the first $40 millionin net profits
from sales of ST-246.) For more information about
PharmAthene.
Ce noodl a été diffusé par PharmAthene Inc. et initialement mise en ligne sur le site http://www.pharmathene.com. La version originale est disponible ici.
Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-11 20:23:08 PM et restera accessible depuis ce lien permanent.
Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
ALTIMMUNE INC 
By 
